4Weber MA,Krix M,Delorme S. Quantitative evaluation of muscle perfusion with CEUS and with MR[J]. Eur Radiol, 2007,17 (10) : 2663- 2674.
5Hirsbberg B, Qiu M, Call AM, et al. Pancreatic perfusion ofhealthy individuals and type 1 diabetic patients as assessed by magnetic resonance perfusion imaging[J]. Diabetologia, 2009,52 (8):1561 -1565.
6Costello LC, Franklin RB, Narayan P, et al. Citrate in the diagno- sis of prostate cancer[J]. Prostate, 1999,38(3) : 237- 245.
7Broome DR,Girguis MS, Baron PW, et al. Gadodi-amide- associat ed nephrogenic systemic fibrosis : why radiologists should be con cerned[J]. AJR, 2007,188(2) : 586.
8Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal dialysis patients[J]. Lancet, 2000,356 (9234) : 1000-1001.
9FDA. Public health advisory: update on magnetic resonance ima ging (MRI) contrast agents containing gadolinium and nephro- genie fibrosing dermopathy [EB/OL]. http//www, fda. gov/ Drugs/DrugSafety/PublicHealthAdvisories/ucm124344. htm. 2007 05 23. 2009- 08 11.
10Calamante F, Thomas DL, Pell GS, et al. Measuring cerebral blood flow using magnetic resonance imaging techniques[J]. J Cereb Blood Flow Metab, 1999,19(7) :701- 735.
